Primary mitochondrial dysfunction commonly leads to failure in cellular adaptation to stress. Paradoxically, however, nonsynonymous mutations of mitochondrial DNA (mtDNA) are frequently found in cancer cells and may have a causal role in the development of resistance to genotoxic stress induced by common chemotherapeutic agents, such as cis-diamminedichloroplatinum(II) (cisplatin, CDDP). Little is known about how these mutations arise and the associated mechanisms leading to chemoresistance. Here, we show that the development of adaptive chemoresistance in the A549 non-small-cell lung cancer cell line to CDDP is associated with the hetero-to homoplasmic shift of a nonsynonymous mutation in MT-ND2, encoding the mitochondrial Complex-I subunit ND2. The mutation resulted in a 50% reduction of the NADH:ubiquinone oxidoreductase activity of the complex, which was compensated by increased biogenesis of respiratory chain complexes. The compensatory mitochondrial biogenesis was most likely mediated by the nuclear co-activators peroxisome proliferator-activated receptor gamma co-activator-1a (PGC-1a) and PGC-1b, both of which were significantly upregulated in the CDDP-resistant cells. Importantly, both transient and stable silencing of PGC-1b re-established the sensitivity of these cells to CDDP-induced apoptosis. Remarkably, the PGC-1b-mediated CDDP resistance was independent of the mitochondrial effects of the co-activator. Altogether, our results suggest that partial respiratory chain defects because of mtDNA mutations can lead to compensatory upregulation of nuclear transcriptional co-regulators, in turn mediating resistance to genotoxic stress.
INTRODUCTION
The mitochondrial genome has a key role in governing the function of mitochondria, encoding 13 essential protein subunits of four large multi-protein oxidative phosphorylation (OXPHOS) complexes, together with mitochondrial ribosomal and transfer RNAs for their translation. The balance between the expression of mitochondrial and nuclear DNA-encoded genes profoundly impacts on overall cellular function and cell fate. 1 Indeed, primary mitochondrial dysfunction because of mutations of mitochondrial DNA (mtDNA) has been recently recognized as a major culprit in ageing and age-related degenerative diseases, and is often associated with loss of cellular proliferation, senescence and cell death. [2] [3] [4] Paradoxically, recent studies have demonstrated mtDNA mutations to occur in virtually all cancers analysed, 5, 6 suggesting that primary mitochondrial dysfunction may also be associated with increased cellular proliferation and resistance to cellular stress-induced cell death. [7] [8] [9] Alongside a potential role in tumour development, studies using cellular cybrid models carrying nonsynonymous mtDNA mutations have recently provided evidence for a causal role of genetic alteration of mtDNA in the development of resistance to DNA damage inducing chemotherapeutic agents. [10] [11] [12] However, the mechanism by which mtDNA mutations confer chemoresistance has not yet been clarified or directly addressed.
Primary mitochondrial dysfunction in cancer cells leads to the activation of a wide array of metabolic and signalling pathways, frequently associated with reactive mitochondrial biogenesis to compensate for the energy deficit caused by defects in the respiratory chain (reviewed in Jones et al. 13 ). This response requires the concerted transcriptional activation of nuclearencoded mitochondrial genes, primarily coordinated by the peroxisome proliferator-activated receptor gamma co-activator-1 (PGC-1) family of nuclear coactivators.
14 Members of the PGC-1 family are recruited to a set of transcription factors, directly mediating the transcription of mitochondrial genes orchestrating biogenesis of the organelle. 15, 16 PGC-1 isoforms are targets of signalling pathways triggered by mitochondrial dysfunction, thus representing a 'retrograde' mitochondrion-nuclear negative feedback loop. 13, 17 In differentiated cells this pathway operates to re-establish the disturbed energetic balance, but in cancer cells activation or overexpression of PGC-1 family proteins has also been suggested to promote proliferation and stress resistance. 18, 19 However, previous studies have not evaluated the role of this pathway induced by primary mitochondrial dysfunction in the development of adaptive chemoresistance to the most commonly used cancer therapeutics, DNA damage inducing agents. We have developed a model in which tumour cell adaptation to long-term genotoxic stress caused by the chemotherapeutic agent cisdiammine-dichloroplatinum (CDDP) was associated with the accumulation of mtDNA mutations, and further studied the contribution of retrograde signalling induced by mitochondrial dysfunction to this adaptive response. 
RESULTS AND DISCUSSION
In order to model adaptive chemoresistance to DNA damage inducing agents we exposed A549 non-small-cell lung cancer cells (A549 WT ) to a low concentration of CDDP (5 mM) for 6 months in culture. The treatment led to the development of a polyclonal, stably CDDP-resistant cell line (A549 CR , Figures 1a-d) . Importantly, five monoclonal cell lines (CR1-5, Figure 1e ), isolated from the polyclonal A549 CR line, all showed similar resistance to CDDP treatment (Figure 1e ), suggesting that they share a common mechanism responsible for the resistance. The development of CDDP resistance had no effect on the modality of CDDP-induced cell death, as in both A549 WT and A549 CR cells it was mediated primarily by the apoptotic pathway, shown by FACS analysis (Figures 1a-d) . Accordingly, the pan caspase inhibitor zVAD-FMK (Figures 1b-d) prevented CDDP-induced cell death in the A549 WT cells (Figure 1f ), whereas the calpain inhibitor ALLN, the caspase-8 inhibitor iETD-FMK and blockade of mitochondrial permeability transition by cyclosporin A had no effect, implicating the intrinsic apoptotic pathway as the route of cell death (Figures 1g-i) .
Next we asked whether the development of the chemoresistant phenotype was associated with genetic and functional alterations of mitochondria. Full-length mitochondrial genome resequencing 20 revealed 16 known polymorphism in the A549 WT mtDNA compared with the revised Cambridge Reference Sequence, 21 of which 7 had previously been associated with cancer (www.mitomap.org, see Supplementary Table 1 ). In addition, the mtDNA of A549 WT cells also contained a novel nonsynonymous point mutation, m.4587T4C (Phe40Leu) in the MT-ND2 gene, encoding the ND2 subunit of NADH:ubiquinone oxidoreductase (Complex-I), in a low-percentage (B25-35%) heteroplasmic state. Importantly, this heteroplasmic mutation drifted to homoplasmy in all the A549 CR cell lines, raising the possibility of positive selection for this genetic variant during the course of adaptation to CDDP exposure (Figure 2a ). The mtDNA of A549 CR cells also contained a novel point mutation (m.225G4T) in the mtDNA D-loop region in a homoplasmic state. Nonsynonymous mutations in the coding region of the mitochondrial genome can cause functional defects in electron transport chain complex activities, while the D-loop has been implicated in the maintenance of mtDNA. 22 To determine whether the ND2 Phe40Leu mutation affects the NADH oxidase and/or ubiquinone-reductase activity of Complex-I, we measured its rotenone-insensitive (diaphorase) and rotenone-sensitive (ubiquinone-reductase) activity. Although the rotenone-insensitive activity of Complex-I to an artificial electron acceptor was not affected, the rotenone-sensitive NADH-oxidation was reduced by 50% in A549 CR relative to the A549 WT cells (Figure 2b ). These results suggest that the mutation impairs electron transfer to ubiquinone by the complex, but does not affect its diaphorase-type activity, consistent with the localization of ND2 adjacent to the Complex-I ubiquinone binding site. 23, 24 The m.225G4T D-loop mutation occurs within the region of the mtDNA heavy-strand origin of replication (O H ); 25 however, we found no difference in mtDNA copy number between A549 WT and A549 CR cells (Figure 2c) , indicating that the m.225G4T D-loop mutation does not affect mtDNA maintenance.
In the next set of experiments we addressed the consequences of the mtDNA mutations on cellular metabolism in A549 CR cells. Surprisingly, in spite of the reduced Complex-I activity, analysis of oxygen consumption rate with the Seahorse XF24 analyser (Seahorse Bioscience, Chicopee, MA, USA) showed no differences between the A549 WT and A549 CR cell lines (Figure 2d ), suggesting that a compensatory mechanism restores OXPHOS to normal levels in the mitochondria of A549 CR cells. Similarly, we observed no alterations in mitochondrial structure and volume (Figure 2e ). The overall mitochondrial oxidative capacity is controlled by mitochondrial biogenesis, involving the coordinated expression of a set of nuclear-encoded mitochondrial genes, as well as increased replication and/or transcription of the mitochondrial genome. 15, 16 Thus, to examine whether increased mitochondrial biogenesis is responsible for the compensatory upregulation of OXPHOS in A549 CR cells, we analysed the expression of nuclear-encoded subunits of each of the OXPHOS complexes (I-V) as well as the mtDNA-encoded COX1 subunit of Complex-IV, each of which reflect the abundance of the fully assembled complex. A549 CR cells showed significant upregulation of each of these proteins as compared with the A549 WT cell line (Figure 3a) , suggesting activation of the mitochondrial biogenesis pathway. The PGC-1 family of nuclear coactivators (PGC-1a, PGC-1b and PRC) coordinate the concerted activation of transcription factors implicated in mitochondrial biogenesis and mitochondrial dysfunction caused by nonsynonymous mtDNA mutations, which has been suggested to trigger mitochondrial biogenesis via PGC-1 isoforms through a mitochondrion-nucleus retrograde signalling pathway (reviewed in Jones et al. 13 ). Indeed, the transcription of both PGC-1a and PGC-1b was significantly upregulated in A549 CR cells compared with the A549 WT cell line (Figure 3b) . In order to demonstrate a corresponding increase in the activity of these nuclear coactivators, we measured the mRNA levels of their known targets. PGC-1a and PGC-1b directly stimulate the transcription factors NRF-1, 2 (nuclear respiratory factor 1 and 2), o C for 10 min, and stored on ice until the start of the assay. One microgram per ml PI (Sigma-Aldrich) was added to cell suspensions immediately before measurement. Fluorescence was measured using a CyAN ADP flow cytometer (Beckman-Coulter, High Wycombe, UK) using 405 nm and 488 nm excitation wavelengths. A minimum population size of 50 000 cells was assayed under each experimental condition. Data were analysed using Summit 4.3 software (Beckman-Coulter) using threshold Hoechst and PI fluorescence intensities set according to non-treated control A549 WT and A549 CR cells to discriminate between live (PI À ) and dead (PI þ ) cells. (d, e) CDDP induced mitochondrial depolarization and cell death in polyclonal (A549 CR ) and monoclonal (CR1-5) CDDP-resistant cell lines. To measure the proportion of cells with depolarized mitochondria, cells were loaded with the cationic dye 3,3 0 -dihexyloxacarbocyanine-iodide (DiOC 6 ), 3 before PI staining, as previously described. 37 The CR1-5 monoclonal A549 cells were generated by dilution from the A549 CR line. CDDP sensitivity on E was calculated by normalizing the DiOC 6 3 negative fraction to A549 WT following CDDP treatment. (f-i) Characterization of the cell death pathway induced CDDP. For cell death inhibition experiments, A549 WT cells were incubated in normal cell culture medium in the presence of 20 mM zVAD-FMK pan-caspase inhibitor (f, Enzo Life Sciences, Exeter, UK), 20 mM z-iETD-FMK caspase-8 inhibitor (g, Enzo Life Sciences, Exeter, UK), 5 mM cyclosporin A cyclophilin-D mitochondrial permeability transition inhibitor (h, Sigma-Aldrich) and 50 mM ALLN calpain inhibitor (i, Enzo Life Sciences, Exeter, UK), or in the presence of the inhibitors and 75 mM CDDP for 24 h before FACS analysis as in (b). Mean ± s.e.m. of at least three independent experiments are shown on the figure. Statistical analyses were performed using Prism 5 for Mac OSX (GraphPad Software Inc., La Jolla, CA, USA). One-way analysis of variance and Bonferroni post analysis, as well as t-test were applied to determine P values. *Po0.05, **Po0.01. Resequencing of the entire 16.5 kb mitochondrial genome, amplified in two fragments from total genomic DNA using long PCR, was performed using the GeneChip Human Mitochondrial Resequencing Array 2.0 according to the Affymetrix CustomSeq Resequencing protocol as previously described in Rahman et al. 20 Sequences were analysed using GSEQ 4.2 software (http://www.ub.edu/ gcai/gseq/index.html). SNPs were automatically called by GSEQ and manually inspected in a SNP viewer format. For Sanger resequencing two different sets of primers were used to amplify the respective mtDNA fragments (primers for mtDNA analysis available upon request). PCR reactions were performed in a final volume of 25 ml, using BioTaq DNA Polymerase (Bioline USA Inc., Boston, MA, USA), as follows: one cycle at 95 1C for 2 min, followed by 30 cycles at 95 1C for 30 s, 50 1C for 30s, and 721C for 40s, and finally one cycle at 72 1C for 5 min. PCR products were purified by Microclean (Microzone Limited, Haywards Heath, UK), directly sequenced using the Big Dye v3.1 Terminator System (Invitrogen, Paisley, UK) and analysed on an automated sequencer (ABI 3130, Applied Biosystems, Carlsbad, CA, USA). Sequence data were analysed using Sequencher (version 4.8) and sequences were compared with the human mtDNA consensus sequence, NCBI reference sequence: NC_012920.1. (b) The effect of the MT-ND2 mutation on Complex-I activity in A549 CR cells. Rotenone-sensitive Complex-I activity (left panel) was measured as previously described. 38 Before analysis cells were subjected to three cycles of freezing and thawing for cell lysis, and rotenone-sensitive decrease in NADH at 340 nm using an Uvikon 940 spectrophotometer (Kontron Instruments Ltd, Watford, UK) at 30 1C was detected. Rotenone-insensitive (diaphorase) activity (right panel) was measured using a Complex-I enzyme activity microplate assay kit (MS141, MitoSciences, Eugene, OR, USA) according to the manufacturer's instructions. Complex-I was immuno-captured within the wells of the microplate from whole-cell lysates and the activity was determined by measuring the oxidation of NADH and the simultaneous reduction and increased absorbance at 450 nm of a proprietary dye. All activities were normalized to total protein input. In A549 rho0 cells mtDNA was depleted as described in Lo et al. 39 (c) mtDNA copy number in A549 WT and A549 CR cells. qPCR was carried out as in Ruhanen et al. 43 with primers that amplify the regions of mtDNA-encoded ND4 gene and nuclear b-actin gene as a nuclear standard. The mtDNA copy number is expressed with normalization relative to the nuclear gene content of the sample. (d) Oxygen consumption rate (OCR, middle panel) in A549 WT and A549 CR cells. OCR was measured using XF24 cell culture microplates by the Seahorse XF24 Analyser. Parental and CDDP-resistant A549 cells were seeded at an average density of 2 Â 10 5 per well. The assay was performed according to the manufacturers protocol as in Traba et al.
40
Uncoupled, maximal and non-mitochondrial respiration was determined after the addition of 5 mM oligomycin, 1 mM carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) and 2 mM antimycin-A, respectively (right panel). All chemicals were from Sigma-Aldrich. (e) Mitochondrial structure and volume in A549 WT and A549 CR cells. Cells were loaded with 5 mM Calcein-AM and 50 nM MitoTracker Red (Invitrogen; 37 1C, 30 min) in a modified Krebs-Ringer buffer (125 mM NaCl, 5 mM KCl, 1 mM Na 3 PO 4 , 1 mM MgSO 4 , 1 g/l glucose, 20 mM HEPES, 1 mM CaCl 2 , pH 7.4, 37 1C, 1 h) and Z-series of images were acquired using a Zeiss LSM 510 system (Carl Zeiss, Inc., Cambridge, UK), as previously described. 41 Maximal projection of images (left panel) were used to quantify the area of green (Calcein) and red (mitoTracker Red) signal. Mitochondrial area was defined relative to cytoplasmic area as 'area red/area green' (middle panel). Representative single-plane images of the mitochondrial structure are shown on the right panel. Statistical analyses were performed using Prism 5 for Mac OSX (GraphPad Software). Mean±s.e.m. is shown on all panels. *Po0.05. and in turn induce the transcription of a large set of nuclear genes encoding mitochondrial proteins. Although the mRNA transcript levels of NRF-1 and NRF-2 remained unchanged (Figure 3c ), we observed increased transcription of a group of nuclear-encoded mitochondrial genes in A549 CR cells relative to A549 WT cells, including CYTC, NDUFV2, SDHA and SDHD, COX4I and COX5B of Complexes I, II and IV, respectively (Figure 3d ). The mRNA abundance of mitochondrial transcription factor A was similar in the two cell lines, consistent with the observed parity in mtDNA copy number (see Figure 2c) . Importantly, the transcriptional activation of nuclear genome-encoded mitochondrial genes was primarily PGC-1a dependent, as shown by the quantification of the mRNA levels of the same gene set following transient silencing of PGC-1a and PGC-1b in A549 CR cells (Figure 3e ). The siRNA (small interfering RNA)-mediated knockdown of PGC-1a, but not PGC-1b, re-established their mRNA levels similar to that of the A549 WT cell line (Figure 3e ). These results indicate that A549 CR cells maintained the same OXPHOS activity as the parental A549 PGC-1b mediates adaptive chemoresistance Z Yao et al Figure 3 . PGC-1-mediated induction of mitochondrial biogenesis in A549 CR cells. (a) Representative western blot (left panel) and quantification (right panel) of the expression of respiratory chain complex subunits in A549 WT and A549 CR cells. Cells were washed with PBS on ice and lysed directly in lysis buffer consisting of 4% SDS (w/v), 20% glycerol and 125 mM Tris-HCl, pH 6.8. Total cellular protein concentration was quantified using the Pierce BCA protein assay kit (GE Healthcare, Chalfont St Giles, UK) according to the manufacturer's instructions, and 30 mg of sample protein diluted in loading buffer consisting of 1% SDS (w/v), 50% sucrose (w/v), bromophenol blue, 10% b-mercaptoethanol and 0.625 mM Trisbase, pH 6.6. Samples were separated by electrophoresis on NuPAGE 4-12% polyacrylamide gels (Invitrogen) and electroblotted onto PVDF membranes (Millipore, Billerica, MA, USA). Membranes were incubated in PBS þ 0.05% Tween-20 (PBST) þ 5% fat-free milk or PBST þ 5% bovine serum albumin (BSA) for 1 h at room temperature before the addition of the primary antibodies. MitoProfile Total OXPHOS Rodent antibody cocktail (raised in mouse (MitoSciences, MS604)) was diluted 1:250 in PBST containing 5% fat-free milk and incubated with membranes overnight at 4 1C. The kit detects the mtDNA-encoded COX1 subunit (shown in red). In addition, the nuclear-encoded Complex-IV subunit COX4 (no. 4844, 1:1000, New England Biolabs, Ipswich, MA, USA) and grp-75 (sc-1058, 1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies were used. Membranes were incubated with respective horseradish peroxidase-conjugated secondary antibodies (Thermo Scientific, Epsom, UK) diluted 1:4000 in PBST þ 5% fat-free milk for 1 h at room temperature, and visualized using the ECL Plus Western Blotting Detection System (GE Healthcare) on a ChemiDoc XRS system (Bio-Rad, Herts, UK). Quantification of protein band intensity was performed using ImageJ software (http://rsbweb.nih.gov/ij/). Intensities of the respective Mitoprofile bands were normalized to the grp-75 band. (b-d) Relative mRNA levels of PGC family coactivators and their target genes in A549 WT and A549 CR cells: transcription factors NRF-1, NRF-2 (GBAP), mitochondrial transcription factor A (TFAM), the NDUFV2 (Complex-I), SDHA and SDHD (Complex-II), COX4I and COX5B (Complex-IV), as well as of CYTC. mRNA levels were measured using RT-qPCR. Total cellular RNA longer than 200 nucleotides in length was isolated using the RNeasy Kit (Qiagen, Sussex, UK) according to the manufacturer's instructions and RNA quality was control as A 260 /A 280 ratio above 1.9. cDNA was synthesized from 1 mg total RNA using Superscript II reverse transcriptase (Invitrogen) and Oligo(dT) primer (Invitrogen) according to the manufacturer's instructions. RT-PCR was performed using a Mastercycler Realplex RT-qPCR system (Eppendorf) through 40 cycles of 95 1C for 15 s and 60 1C for 60 s, using TaqMan Gene Expression Assays (Applied Biosystems) specific for PGC-1a (Hs00173304_m1), PGC-1b (Hs00370186_m1), PRC (Hs00209379_m1), NRF-1 (Hs00602161_m1), NRF-2 (Hs00745591_s1), TFAM (Hs00273372_s1) and TUBB (Hs00742828_s1). Quantification was made using the comparative threshold method (2 À DDCt ) normalizing data to TUBB and A549 WT samples. The respiratory complex subunits and TUBB as endogenous control were measured using SYBR Green JumpStart Taq ReadyMix for QPCR (Sigma, Dorset, UK) and specific primers for those genes designed using the Sigma OligoArchitect design tool. The oligomer sequences and the reaction conditions are shown in Supplementary Table 2. Quantification was made by first calculating the copy number of each gene normalized to TUBB and than normalized to A549 WT samples. (e) Transient PGC-1a and b silencing in A549 CR cells reduces the mRNA levels of respiratory complex subunits to that of A549 WT cells. Cells were either non-transfected or were transfected with 10 nmol siGENOME Non-Targeting siRNA no. 2 (D-001210-02-20, scr), PPARGC1A (M-005111-01-0005, PGC-1a) or PPARGC1B (M-008556-00-0005, PGC-1b) SMARTpool siRNA (Dharmacon, Lafayette, CO, USA). Transfections were carried out using 6 ml of DharmaFECT and 10 ml of siRNA (20 mM stock) in 2 ml normal culture medium according to the manufacturer's protocol. Relative mRNA levels are normalized to Scr-transfected A549 CR cells. SYBR Green based RT-PCR was performed as described in (d). The oligomer sequences and reaction conditions for PGC1A and PGC1B are also shown in Supplementary Table 2 Figure 2f were used, applying Akt (pan, C67E7) and Phospho-Akt (Ser473) primary antibodies (Cell Signalling Technology, Danvers, MA, USA). Statistical analyses were performed using Prism 5 for Mac OSX (GraphPad Software). Two-way analysis of variance and Bonferroni post analysis, as well as t-test were applied to determine P values. On (a) data were analysed for A549 WT vs A549 CR cells using all subunit densities as the source of variation. Mean±s.e.m. is shown on all panels. *Po0.05. , 37 1C, 15 min) . Image acquisition and analysis was performed using the Arrayscan VTI HCS Reader (Thermo Scientific), according to a modified Cell Viability Assay protocol (K0200011). Hoechst-stained nuclei were imaged using the standard 365(50) nm excitation/535(45) nm emission filter set. Images were used to determine objects for total cell number counting. PI intensity in the Hoechst defined objects was quantified after background subtraction using the 535 nm 35 excitation/590nm 35 emission filter set. The threshold for counting PI þ cells was determined based on intensities of the non-treated and CDDPtreated parental A549 cell population, and was applied throughout the whole set of experiments. (b) CDDP-(75 mM) induced cell death in parental and rho0 (mtDNA depleted) A549 cells (see Figure 2b) . Cell death was quantified by FACS analysis as described in Figure 1b. (c-e) PGC-1b knockdown abolishes CDDP resistance in the A549 CR cell line. (c) Transient silencing of PGC-1a and PGC-1b was achieved as described in Figure 2e . Cell death was induced by 75 mM CDDP treatment 48 h after transfection and was quantified by imaging as described in (a). (d) Stable clones with non-targeting, PGC-1a-targeting and PGC-1b-targeting shRNAs were generated by using shRNAmir constructs from the Open Biosystems Human GIPZ shRNAmir lentiviral library (Thermo Scientific, available from the UCL Cancer Institute). Cells were transfected with non-silencing (RHS4346), PGC-1a-targeting (V2LHS_71173) and PGC-1b-targeting (V2LHS_18251) pGIPZ constructs and selected using 1 mg/ml puromycin. Clones with highest GFP expression were selected. Cell death, induced by 75 mM CDDP was quantified by imaging as described in (a). *Po0.05 compared with Scr clones; no. Po0.05 compared with Parental. (e) Silencing efficiency of PGC-1a and PGC-1b mRNA in the shRNA clones. Relative mRNA levels were measured by RT-PCR as described in Figure 2 . (f) CDDP reduces basal OCR to similar extent in both A549 WT and A549 CR cells. OCR was measured as described in Figure 2d in controls and after CDDP treatment (75 mM, 24 h). Data are normalized to non-treated control cells. (g) Reduced glutathione levels do not differ between A549 WT and A549 CR cells. Reduced cellular glutathione levels (GSH) were measured by quantitative imaging of monochlorobimane (MCB) loaded A549 WT and A549 CR cells. Cells were loaded with 50 mM MCB in KRB. To deplete the cellular GSH pool, control cells were incubated in KRB in the presence of 50 mM diethylmaleate (DEM) for 15 min before MCB loading. MCB loading time was determined by measuring MCB fluorescence in cells during the dye-loading period, the point at which no further change in fluorescence was detected representing the point of GSH saturation. MCB fluorescence was measured using a using an Olympus IX71 inverted epifluorescence microscope (Olympus, Essex, UK) fitted with a computer controlled motorized stage (Applied Scientific Instrumentation, Eugene, OR, USA) with a Â 40 fluorite objective lens (NA 0.6) and a full-enclosure environmental chamber heated to 37 1C (Digital Pixel Imaging, Brighton, UK). Images were collected using a Hamamatsu C10600-10B CCD camera (Hamamatsu Corporation, Hamamatsu, Japan), and recorded and analysed using Simple PCI 6.6.0.0 software (Hamamatsu Corporation). Illumination was provided by light from a metal halide arc lamp passing through a computer controlled filter wheel (Prior Scientific, Cambridge, UK) and a 84000v2 Quad filter set (Chroma Technology, Bellows Falls, VT, USA), using a D-350/50x excitation filter (Chroma Technology Corp., Olching, Germany). Ten images containing a minimum of 20 cells per image field were collected under each individual condition, and mean MCB fluorescence calculated using MetaMorph 6.1 software (Molecular Devices, Sunnyvale, CA, USA). Fluorescence intensities were normalized relative to non-treated A549 WT cells. Mean ± s.e.m. of at least three independent experiments are shown. Statistical analyses were performed using Prism 5 for Mac OSX (GraphPad Software). One-way analysis of variance and Bonferroni post analysis were applied to determine P values. *Po0.05, **Po0.01.
cell line by PGC-1a-mediated mitochondrial biogenesis, offsetting the reduced intrinsic activity of Complex-I because of the MT-ND2 mutation.
Next, in order to address the mechanism leading to the transcriptional activation of PGC-1a and PGC-1b, we tested the contribution of previously known mitochondrion-nuclear signalling pathways to the response. Although there is strong evidence for an evolutionarily conserved mitochondria-nucleus retrograde pathway, 17 the nature of such signalling in mammalian cells is not well understood. The direct consequences of mitochondrial dysfunction involve dysregulation of Ca 2 þ homeostasis, increased ROS generation and/or changes in redox equilibrium such as alterations in the NADH:NAD þ ratio. In order to assess the potential role of ROS in mitochondrial-nuclear signalling, we measured mitochondrial and cytosolic superoxide and hydrogen peroxide levels (Supplementary Figure S1) . We observed no difference in the cytosolic parameters between the two cell lines, excluding the role of ROS as a retrograde signal. Increased cytoplasmic Ca 2 þ levels have been reported to activate the insulin-like growth factor receptor 1 in a calcineurin-dependent manner, leading to activation of Akt-1. 26 In addition, Akt-1 was suggested to confer protection against CDDP-induced cell death. 27 However, in marked contrast to these previous findings, we detected reduced Akt Ser473 phosphorylation in the CDDPresistant cells as compared with the parental cell line (Figure 3f ). These results exclude direct Akt-1-mediated protection against CDDP-induced cell death in A549 CR cells, but reduced Akt-1 activation might be responsible for both the induction and subsequent activation of PGC-1a. 28 Finally, inhibition of Complex-I activity is likely to result in the accumulation of NADH, a situation which has recently been shown to mediate transcriptional responses regulating mitochondrial function. 29, 30 The role of such pathways in mediating mitochondrial biogenesis needs further investigation.
In the final set of experiments, we addressed the question as to whether mitochondrial dysfunction and elevated PGC-1a and PGC-1b co-activation has a role in mediating the CDDP-resistant phenotype of A549 CR cells. First, in order to test whether partial reduction of OXPHOS capacity is functionally implicated in the CDDP-resistant phenotype, we treated the A549 WT cell line with low, sub-optimal concentrations of rotenone to partially inhibit Complex-I. Pre-treatment with 20-50 nM rotenone for 72 h before CDDP treatment reduced CDDP-induced cell death in the A549 WT cells (Figure 4a ), indicating the important role of Complex-I in determining cellular sensitivity to CDDP. Moreover, A549 rho0 cells, which are devoid of mtDNA, also showed remarkable resistance to CDDP-induced cell death ( Figure 4b) .
Next, we investigated whether PGC-1a or PGC-1b might be directly responsible for the CDDP-resistant phenotype. We first transfected the A549 CR cells with siRNAs targeting PGC-1a or PGC1b and compared CDDP-mediated cell death between these groups and non-transfected cells or cells transfected with nontargeting siRNAs (Figure 4c ). The transient knockdown of PGC-1a had no effect on CDDP-induced cell death, whereas silencing of PGC-1b caused an almost twofold increase in CDDP sensitivity of A549 CR cells, indicating a specific role for the b isoform of the PGC-1 co-activator in CDDP resistance. To confirm these results, we created A549 CR clones with stable knockdown of the coactivators parallel with scrambled control clones using the pGIPZ vector system. Three separate clones stably transfected with a shRNA (short hairpin RNA) targeting PGC-1b showed an approximately twofold increase in sensitivity to CDDP treatment as compared with untransfected cells and control cells expressing scrambled shRNA (Figure 4d ). Targeting the PGC-1a isoform had no effect on CDDP-induced cell death. Evaluation of the efficiency of silencing by qPCR showed at least 50% reduction of both PGC-1a and PGC-1b mRNAs (Figure 4e ). These results demonstrated that knockdown of PGC-1b is necessary and sufficient to revert the CDDP-resistant phenotype in A549 CR cells. We note that stable silencing of PGC-1b in the shRNA clones was accompanied by a concomitant significant downregulation of PGC-1a mRNA (Figure 4e ), although this effect was not observed following transient siRNA transfection targeting PGC-1b (Figure 3e ). Stable knockdown of the PGC-1a isoform alone did not alter A549 CR cell CDDP sensitivity or the level of transcription of PGC-1b. These results clearly demonstrate a role for the activity of PGC-1 coactivators in modulating cellular sensitivity to genotoxic stress; however, whether increased A549 CR cell death in clones stably expressing PGC-1b shRNA is a consequence of PGC-1b knockdown alone or also requires the consequent loss of PGC-1a activity, remains under investigation. However, the fact that both transient and stable knockdown of PGC-1b, but not PGC-1a, restored CDDP sensitivity to A549 CR cells supports a dominant role for PGC-1b in mediating cytoprotection under genotoxic stress in this system.
Finally, in order to investigate the mechanism by which PGC-1b protects cells against CDDP-induced cell death, we tested the two known functions of the co-activator: maintenance of the OXPHOS competence and stimulation of cellular antioxidant defence systems. 31, 32 CDDP treatment in both A549 WT and A549 CR cells led to partial reduction of OXPHOS function (Figure 4f) , likely owing to the direct effect of the drug on mitochondria. 33 The extent of inhibition was comparable to the two cell lines, showing that PGC-1b does not mediate cytoprotection by stimulating mitochondrial biogenesis and function in A549 CR cells following CDDP exposure. ROS has been previously suggested to have a key role in DD-induced cell death. 34 In order to test whether resistance to CDDP was mediated by increased mitochondrial and cellular oxidative defence capacity, we assessed the role of ROS in cell death induction in A549 WT and A549 CR cells. The steady-state cellular glutathione (GSH) levels did not differ between the two cell lines (Figure 4g) , and CDDP treatment did not result in significant depletion of GSH levels in either cell type. Moreover, time-lapse measurements of mitochondrial ROS accumulation in A549 WT cells (Supplementary Figure S1D) and the lack of effect of the superoxide dismutase mimetic TEMPOL on CDDP-induced cell death in A549 WT cells (Supplementary Figure S1E) indicated that ROS has no direct mechanistic role in CDDP-induced cell death in this cellular model. Altogether, these results showed that PGC-1b mediates the CDDP-resistant phenotype in A549 CR cells, which, however, does not involve the mitochondrial biogenetic and antioxidant functions of this co-regulator. Most of the target genes whose expression is implicated in these two established functions are regulated by both PGC-1b and PGC-1a. However, recent studies indicate that a separate set of genes is specifically affected by the ablation of PGC-1b in the presence of an intact PGC-1a background. 15, 35, 36 Further studies of this gene set will potentially reveal the exact mechanism by which PGC-1b regulates the DNA damage-induced cell death pathway.
